Development of a miRNA-seq based prognostic signature in lung adenocarcinoma

Abstract Background We utilized miRNAs expression and clinical data to develop a prognostic signature for patients with lung adenocarcinoma, with respect to their overall survival, to identify high-risk subjects based on their miRNA genomic profile. Methods MiRNA expressions based on miRNA sequencin...

Full description

Bibliographic Details
Main Authors: Chathura Siriwardhana, Vedbar S. Khadka, John J. Chen, Youping Deng
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-018-5206-8
id doaj-ff4d57c2d03540898e3c376a6db91bb1
record_format Article
spelling doaj-ff4d57c2d03540898e3c376a6db91bb12020-11-25T02:08:03ZengBMCBMC Cancer1471-24072019-01-0119111010.1186/s12885-018-5206-8Development of a miRNA-seq based prognostic signature in lung adenocarcinomaChathura Siriwardhana0Vedbar S. Khadka1John J. Chen2Youping Deng3Bioinformatics and Biostatistics Cores, Department of Complementary and Integrative Medicine, University of Hawaii John A. Burns School of MedicineBioinformatics and Biostatistics Cores, Department of Complementary and Integrative Medicine, University of Hawaii John A. Burns School of MedicineBioinformatics and Biostatistics Cores, Department of Complementary and Integrative Medicine, University of Hawaii John A. Burns School of MedicineBioinformatics and Biostatistics Cores, Department of Complementary and Integrative Medicine, University of Hawaii John A. Burns School of MedicineAbstract Background We utilized miRNAs expression and clinical data to develop a prognostic signature for patients with lung adenocarcinoma, with respect to their overall survival, to identify high-risk subjects based on their miRNA genomic profile. Methods MiRNA expressions based on miRNA sequencing and clinical data of lung adenocarcinoma patients (n = 479) from the Cancer Genome Atlas were randomly partitioned into non-overlapping Model (n = 320) and Test (n = 159) sets, respectively, for model estimation and validation. Results Among the ten miRNAs identified using the univariate Cox analysis, six from miR-8, miR-181, miR-326, miR-375, miR-99a, and miR-10, families showed improvement of the overall survival chance, while two miRNAs from miR-582 and miR-584 families showed a worsening of survival chances. The final prognostic signature was developed with five miRNAs—miR-375, miR-582-3p, miR-326, miR-181c-5p, and miR-99a-5p—utilizing a stepwise variable selection procedure. Using the KEGG pathway analysis, we found potential evidence supporting their significance in multiple cancer pathways, including non-small cell lung cancer. We defined two risk groups with a score calculated using the Cox regression coefficients. The five-year survival rates for the low-risk group was approximately 48.76% (95% CI = (36.15, 63.93)); however, it was as low as 7.50% (95% CI = (2.34, 24.01)) for the high-risk group. Furthermore, we demonstrated the effect of the genomic profile using the miRNA signature, quantifying survival rates for hypothetical subjects in different pathological stages of cancer. Conclusions The proposed prognostic signature can be used as a reliable tool for identifying high-risk subjects regarding survival based on their miRNA genomic profile.http://link.springer.com/article/10.1186/s12885-018-5206-8Lung adenocarcinomaMiRNAPrognostic signatureSurvival
collection DOAJ
language English
format Article
sources DOAJ
author Chathura Siriwardhana
Vedbar S. Khadka
John J. Chen
Youping Deng
spellingShingle Chathura Siriwardhana
Vedbar S. Khadka
John J. Chen
Youping Deng
Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
BMC Cancer
Lung adenocarcinoma
MiRNA
Prognostic signature
Survival
author_facet Chathura Siriwardhana
Vedbar S. Khadka
John J. Chen
Youping Deng
author_sort Chathura Siriwardhana
title Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
title_short Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
title_full Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
title_fullStr Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
title_full_unstemmed Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
title_sort development of a mirna-seq based prognostic signature in lung adenocarcinoma
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2019-01-01
description Abstract Background We utilized miRNAs expression and clinical data to develop a prognostic signature for patients with lung adenocarcinoma, with respect to their overall survival, to identify high-risk subjects based on their miRNA genomic profile. Methods MiRNA expressions based on miRNA sequencing and clinical data of lung adenocarcinoma patients (n = 479) from the Cancer Genome Atlas were randomly partitioned into non-overlapping Model (n = 320) and Test (n = 159) sets, respectively, for model estimation and validation. Results Among the ten miRNAs identified using the univariate Cox analysis, six from miR-8, miR-181, miR-326, miR-375, miR-99a, and miR-10, families showed improvement of the overall survival chance, while two miRNAs from miR-582 and miR-584 families showed a worsening of survival chances. The final prognostic signature was developed with five miRNAs—miR-375, miR-582-3p, miR-326, miR-181c-5p, and miR-99a-5p—utilizing a stepwise variable selection procedure. Using the KEGG pathway analysis, we found potential evidence supporting their significance in multiple cancer pathways, including non-small cell lung cancer. We defined two risk groups with a score calculated using the Cox regression coefficients. The five-year survival rates for the low-risk group was approximately 48.76% (95% CI = (36.15, 63.93)); however, it was as low as 7.50% (95% CI = (2.34, 24.01)) for the high-risk group. Furthermore, we demonstrated the effect of the genomic profile using the miRNA signature, quantifying survival rates for hypothetical subjects in different pathological stages of cancer. Conclusions The proposed prognostic signature can be used as a reliable tool for identifying high-risk subjects regarding survival based on their miRNA genomic profile.
topic Lung adenocarcinoma
MiRNA
Prognostic signature
Survival
url http://link.springer.com/article/10.1186/s12885-018-5206-8
work_keys_str_mv AT chathurasiriwardhana developmentofamirnaseqbasedprognosticsignatureinlungadenocarcinoma
AT vedbarskhadka developmentofamirnaseqbasedprognosticsignatureinlungadenocarcinoma
AT johnjchen developmentofamirnaseqbasedprognosticsignatureinlungadenocarcinoma
AT youpingdeng developmentofamirnaseqbasedprognosticsignatureinlungadenocarcinoma
_version_ 1724927841800290304